FFRct vs Merge PACS
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 60/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
FFRct is a specialized AI diagnostic tool for coronary artery disease, providing detailed blood flow analysis from CCTA scans. In contrast, Merge PACS is an enterprise-level imaging system that manages and archives medical images across modalities, offering a platform for integrating various third-party AI applications. While both operate in cardiology and radiology, FFRct focuses on specific diagnostic analysis, whereas Merge PACS provides the foundational infrastructure for image management and AI workflow integration.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
HeartFlow FFRct Analysis is a non-invasive, AI-powered diagnostic tool that creates personalized 3D models of coronary arteries from CCTA scans to assess blood flow and aid in diagnosing coronary artery disease. Merative Merge PACS is an enterprise-level Picture Archiving and Communication System (PACS) designed to streamline radiology workflows, consolidate imaging data, and integrate AI insights across multi-site health systems.
HeartFlow FFRct Analysis is cloud-based, utilizing CCTA scan data transferred via a local Virtual Appliance for processing and analysis. Merative Merge PACS offers flexible deployment options (on-premise, cloud, hybrid) and is designed for enterprise-wide image management, integrating with EMR/EHR, RIS, HIS, and VNA systems.
HeartFlow FFRct Analysis *is* an AI-powered diagnostic tool that uses AI and computational fluid dynamics to create 3D models and analyze blood flow for CAD diagnosis. Merative Merge PACS *integrates* AI by providing a single worklist for access to third-party AI applications, enhancing diagnostic workflows rather than performing the AI analysis itself.
For HeartFlow FFRct Analysis, there is a specified CMS payment rate of $1,017 for 2025, with commercial payer rates varying. For Merative Merge PACS, pricing details require direct contact with the vendor.
Both HeartFlow FFRct Analysis and Merative Merge PACS are relevant to Cardiology and Radiology specialties. FFRct specifically aids in coronary artery disease diagnosis, while Merge PACS supports multi-modality diagnostic interpretation across these and other imaging-intensive specialties.
Both HeartFlow FFRct Analysis and Merative Merge PACS are HIPAA compliant and FDA cleared. HeartFlow FFRct Analysis explicitly states it has a BAA, and Merge PACS implies BAA availability through its HIPAA and SOC2 compliance, recommending vendor contact for specific BAA details.